Assessments of antibody biodistribution

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S29-S38

  Glassman, Patrick M ^a   Abuqayyas, Lubna ^b   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b AMGEN INC   (United States)

Author keywords

biologics; biotechnology (BTN); pharmaceutics (PCT); pharmacodynamics (PDY); pharmacokinetics and metabolism

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; RADIOMETRY; TISSUE DISTRIBUTION; ANIMAL; BIOLOGICAL MODEL; HUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION;

EID: 84923321220     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.365     Document Type: Article

References (89)

1. Kohler G, Milstein C,. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256 (5517): 495-497.
2. Lobo ED, Hansen RJ, Balthasar JP,. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93 (11): 2645-2668.
3. Garg A, Balthasar JP,. Investigation of the influence of FcRn on the distribution of IgG to the brain. AAPS J. 2009; 11 (3): 553-557.
4. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998; 95 (8): 4607-4612.
5. Brown EB, Boucher Y, Nasser S, Jain RK,. Measurement of macromolecular diffusion coefficients in human tumors. Microvasc Res. 2004; 67 (3): 231-236.
6. Jain RK, Baxter LT,. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res. 1988; 48 (24 Pt 1): 7022-7032.
7. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier. Cancer Res. 1992; 52 (19): 5144-5153.
8. Blumenthal RD, Fand I, Sharkey RM, Boerman OC, Kashi R, Goldenberg DM,. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: An autoradiographic study. Cancer Immunol Immunother. 1991; 33 (6): 351-358.
9. Langmuir VK, Mendonca HL, Woo DV,. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: Uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res. 1992; 52 (17): 4728-4734.
10. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001; 61 (12): 4750-4755.
11. Rudnick SI, Lou J, Shaller CC, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011; 71 (6): 2250-2259.
12. Urva SR, Yang VC, Balthasar JP,. Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody. J Pharm Sci. 2010; 99 (3): 1582-1600.
13. Simister NE, Mostov KE,. An Fc receptor structurally related to MHC class I antigens. Nature. 1989; 337 (6203): 184-187.
14. Borvak J, Richardson J, Medesan C, et al. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol. 1998; 10 (9): 1289-1298.
15. Rodewald R,. PH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol. 1976; 71 (2): 666-669.
16. Junghans RP, Anderson CL,. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA. 1996; 93 (11): 5512-5516.
17. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D,. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest. 2004; 113 (9): 1328-1333.
18. Deng R, Loyet KM, Lien S, et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos. 2010; 38 (4): 600-605.
19. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ,. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: Relationship to pharmacokinetics in mice and primates. Drug Metab Dispos. 2007; 35 (1): 86-94.
20. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Wroblewski VJ,. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem. 2007; 282 (3): 1709-1717.
21. Hansen RJ, Balthasar JP,. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood. 2002; 100 (6): 2087-2093.
22. Jones EA, Waldmann TA,. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest. 1972; 51 (11): 2916-2927.
23. Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL,. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol. 1996; 157 (8): 3317-3322.
24. Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA. 2004; 101 (26): 9763-9768.
25. Garg A, Balthasar JP,. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007; 34 (5): 687-709.
26. Zhang Y, Pardridge WM,. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol. 2001; 114 (1-2): 168-172.
27. Cooper PR, Ciambrone GJ, Kliwinski CM, et al. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Res. 2013; 1534: 13-21.
28. Caram-Salas N, Boileau E, Farrington GK, et al. In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis across the blood-brain barrier. Methods Mol Biol. 2011; 763: 383-401.
29. Abuqayyas L, Balthasar JP,. Investigation of the role of FcγR and FcRn in mAb distribution to the brain. Mol Pharmaceutics. 2012; 10 (5): 1505-1513.
30. Amigorena S, Bonnerot C,. Fc receptor signaling and trafficking: A connection for antigen processing. Immunol Rev. 1999; 172 (1): 279-284.
31. Amigorena S, Bonnerot C,. Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol. 1999; 11 (6): 385-390.
32. Nimmerjahn F, Ravetch JV,. Fcgamma receptors: Old friends and new family members. Immunity. 2006; 24 (1): 19-28.
33. Ravetch JV, Bolland S,. IgG Fc receptors. Annu Rev Immunol. 2001; 19: 275-290.
34. Cassel DL, Keller MA, Surrey S, et al. Differential expression of Fc gamma RIIA, Fc gamma RIIB and Fc gamma RIIC in hematopoietic cells: Analysis of transcripts. Mol Immunol. 1993; 30 (5): 451-460.
35. Siberil S, Dutertre CA, Fridman WH, Teillaud JL,. FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol/. Hematol. 2007; 62 (1): 26-33.
36. Nimmerjahn F, Ravetch JV,. Fcgamma receptors as regulators of immune responses. Nature Rev Immunol. 2008; 8 (1): 34-47.
37. Tarasenko T, Dean JA, Bolland S,. FcgammaRIIB as a modulator of autoimmune disease susceptibility. Autoimmunity. 2007; 40 (6): 409-417.
38. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV,. FcgammaRIV: A novel FcR with distinct IgG subclass specificity. Immunity. 2005; 23 (1): 41-51.
39. Tabrizi M, Bornstein GG, Suria H,. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010; 12 (1): 33-43.
40. Tabrizi MA, Tseng CM, Roskos LK,. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11 (1-2): 81-88.
41. Mould DR, Green B,. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: Concepts and lessons for drug development. BioDrugs. 2010; 24 (1): 23-39.
42. Nishio S, Yamamoto T, Kaneko K, et al. Pharmacokinetic study and Fcgamma receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. Mod Rheumatol/Jpn Rheumatism Assoc. 2009; 19 (3): 329-333.
43. McDonagh CF, Kim KM, Turcott E, et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Therap. 2008; 7 (9): 2913-2923.
44. Zuckier LS, Georgescu L, Chang CJ, Scharff MD, Morrison SL,. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer. 1994; 73 (3 Suppl): 794-799.
45. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99 (3): 754-758.
46. Dornan D, Spleiss O, Yeh RF, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood. 2010; 116 (20): 4212-4222.
47. Abuqayyas L, Balthasar JP,. Application of knockout mouse models to investigate the influence of FcgammaR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. Int J Pharm. 2012; 439 (1-2): 8-16.
48. Abuqayyas L, Zhang X, Balthasar JP,. Application of knockout mouse models to investigate the influence of FcgammaR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. Int J Pharm. 2013; 444 (1-2): 185-192.
49. Jones DH, Nusbacher J, Anderson CL,. Fc receptor-mediated binding and endocytosis by human mononuclear phagocytes: Monomeric IgG is not endocytosed by U937 cells and monocytes. J Cell Biol. 1985; 100 (1985): 558-564.
50. Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S,. Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs. 2013; 5 (6): 896-903.
51. Ghetie V, Ward ES,. Transcytosis and catabolism of antibody. Immunol Res. 2002; 25 (2): 97-113.
52. McKeage K, Perry CM,. Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002; 62 (1): 209-243.
53. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA,. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010; 21 (12): 2153-2163.
54. Khawli LA, Goswami S, Hutchinson R, et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs. 2010; 2 (6): 613-624.
55. Zheng Y, Tesar DB, Benincosa L, et al. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. mAbs. 2012; 4 (2).
56. Igawa T, Tsunoda H, Tachibana T, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010; 23 (5): 385-392.
57. Schifferli JA, Taylor RP,. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 1989; 35 (4): 993-1003.
58. Abuqayyas L, Balthasar JP,. Pharmacokinetic mAb-mAb interaction: Anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts. AAPS J. 2012.
59. Kuester K, Kovar A, Lupfert C, Brockhaus B, Kloft C,. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations. Clin Pharmacokinet. 2009; 48 (7): 477-487.
60. Blasco H, Lalmanach G, Godat E, et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods. 2007; 325 (1-2): 127-139.
61. Boswell CA, Bumbaca D, Fielder PJ, Khawli LA,. Compartmental tissue distribution of antibody therapeutics: Experimental approaches and interpretations. AAPS J. 2012; 14 (3): 612-618.
62. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels. J Nucl Med. 1994; 35 (5): 899-908.
63. Ullberg S,. Studies on the distribution and fate of S35-labelled benzylpenicillin in the body. Acta Radiol Suppl. 1954; 118: 1-110.
64. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999; 27 (5): 536-544.
65. Carter T, Sterling-Levis K, Ow K, et al. Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody. Cancer Immunol Immunother. 2004; 53 (6): 533-542.
66. Fischman AJ, Alpert NM, Rubin RH,. Pharmacokinetic imaging: A noninvasive method for determining drug distribution and action. Clin Pharmacokinet. 2002; 41 (8): 581-602.
67. Wu AM,. Antibodies and antimatter: The resurgence of immuno-PET. J Nucl Med. 2009; 50 (1): 2-5.
68. Fischer G, Seibold U, Schirrmacher R, Wangler B, Wangler C,. (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: Chemistry, Applications and remaining challenges. Molecules. 2013; 18 (6): 6469-6490.
69. Meijs WE, Haisma HJ, Klok RP, et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med. 1997; 38 (1): 112-118.
70. Clauss MA, Jain RK,. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. 1990; 50 (12): 3487-3492.
71. Ballou B, Ernst LA, Waggoner AS,. Fluorescence imaging of tumors in vivo. Curr Med Chem. 2005; 12 (7): 795-805.
72. Spibey CA, Jackson P, Herick K,. A unique charge-coupled device/xenon arc lamp based imaging system for the accurate detection and quantitation of multicolour fluorescence. Electrophoresis. 2001; 22 (5): 829-836.
73. Ramjiawan B, Maiti P, Aftanas A, et al. Noninvasive localization of tumors by immunofluorescence imaging using a single chain Fv fragment of a human monoclonal antibody with broad cancer specificity. Cancer. 2000; 89 (5): 1134-1144.
74. Ogawa M, Kosaka N, Choyke PL, Kobayashi H,. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res. 2009; 69 (4): 1268-1272.
75. Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM,. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem. 2005; 77 (5): 1432-1439.
76. Duan X, Dai L, Chen SC, Balthasar JP, Qu J,. Nano-scale liquid chromatography/mass spectrometry and on-the-fly orthogonal array optimization for quantification of therapeutic monoclonal antibodies and the application in preclinical analysis. J Chromatogr A. 2012; 1251: 63-73.
77. Li H, Ortiz R, Tran LT, et al. Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing. AAPS J. 2013; 15 (2): 337-346.
78. Straughn AB,. Limitations of Noncompartmental Pharmacokinetic Analysis of Biotech Drugs. Pharmacokinetics and Pharmacodynamics of Biotech Drugs. Wiley-VCH Verlag GmbH & Co. KGaA; 2006: 181-188.
79. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M,. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013; 52 (2): 83-124.
80. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH,. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49 (8): 493-507.
81. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28 (6): 507-532.
82. Lammerts van Bueren, Bleeker JJ, Bogh WK, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action. Cancer Res. 2006; 66 (15): 7630-7638.
83. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN,. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab') 2, and Fab' in mice. Cancer Res. 1986; 46 (8): 3969-3978.
84. Baxter LT, Zhu H, Mackensen DG, Jain RK,. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994; 54 (6): 1517-1528.
85. Ferl GZ, Wu AM, DiStefano JJ, III,. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005; 33 (11): 1640-1652.
86. Abuqayyas L, Balthasar JP,. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer. J Pharmacokinet Pharmacodyn. 2012; 39 (6): 683-710.
87. Chen Y, Balthasar JP,. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J. 2012; 14 (4): 850-859.
88. Shah DK, Betts AM,. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012; 39 (1): 67-86.
89. Shah DK, Betts AM,. Antibody biodistribution coefficients: Inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. mAbs. 2013; 5 (2): 297-305.